Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
April 16, 2024 07:05 ET
|
Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
April 15, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Uncle Bud’s Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness
April 11, 2024 10:52 ET
|
Pressure BioSciences, Inc.
PBIO’s UltraShear Platform Enables Development and Launch of Health & Wellness Products with Revolutionary Bioavailability, Onset, and Effectiveness
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
April 11, 2024 04:00 ET
|
Macomics Limited
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancerData presented at AACR 2024 shows MACO-355 is...
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
April 10, 2024 07:30 ET
|
Cytokinetics, Incorporated
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten...
Biometric Technology Market To Reach USD 173.7 Billion By 2032 | DataHorizzon Research
April 10, 2024 03:30 ET
|
DataHorizzon Research
Fort Collins, Colorado, April 10, 2024 (GLOBE NEWSWIRE) -- Need for Identification and Authentication to Propel Industry Growth The growing imperative for secure identification and authentication...
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
April 09, 2024 16:00 ET
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Mass Spectrometry Market Forecast 2024-2034: A $15.5 Billion Global Opportunity with Waters Corporation, Kore Technology, and Danaher Corporation Dominating
April 08, 2024 10:58 ET
|
Research and Markets
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Global Mass Spectrometry Market Analysis & Forecast 2024-2034: Market By Product; By Technology; By Application; By End-user; and By Region"...
World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent
April 08, 2024 07:30 ET
|
World Orphan Drug Alliance (WODA)
World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent